Catalyst Health Ventures
Catalyst Health Ventures (CHV) is a Boston-based venture capital fund that invests in transformative medical technologies addressing global unmet healthcare needs. CHV focuses on therapeutic medical devices, diagnostics, drug delivery and digital health, typically acting as the first institutional investor and supporting companies from seed through Series B and beyond. The firm emphasizes active partnership with founders, providing guidance, network access and support through clinical and regulatory development.
Industries
Nr. of Employees
small (1-50)
Portfolio
Developer of an implantable pulmonary hypertension (PH) system. CHV led or participated in funding rounds (Series A $7.8M; later Series B $31M participation). Aria CV received FDA Breakthrough Device Designation for its PH system and reported first patient implant of the Gen 2 system as part of an ASPIRE PH early feasibility trial (implant completed Feb 14, 2024).
#Medical devices (pulmonary hypertension treatment)
Developing extracardiac temporary and permanent pacing therapies that avoid placing hardware inside the heart. Completed a $25M Series B financing with CHV as an investor; CHV partner Darshana Zaveri to join the board.
#Cardiac pacing / medical devices
Developer of the AngioVac system for extracorporeal removal of thrombus. Vortex Medical was the subject of an acquisition agreement with AngioDynamics (transaction reported in news coverage).
#Endovascular devices / thrombus removal
Listed on CHV's portfolio; specific product or financing details are presented on the company portfolio page.
#Medical devices
CHV-listed portfolio company; Maxwell Health was acquired by Sun Life Financial (reported in CHV news item).
#Digital health / benefits administration software
Developer of an implantable pulmonary hypertension (PH) system. CHV led or participated in funding rounds (Series A $7.8M; later Series B $31M participation). Aria CV received FDA Breakthrough Device Designation for its PH system and reported first patient implant of the Gen 2 system as part of an ASPIRE PH early feasibility trial (implant completed Feb 14, 2024).
#Medical devices (pulmonary hypertension treatment)
Developing extracardiac temporary and permanent pacing therapies that avoid placing hardware inside the heart. Completed a $25M Series B financing with CHV as an investor; CHV partner Darshana Zaveri to join the board.
#Cardiac pacing / medical devices
Developer of the AngioVac system for extracorporeal removal of thrombus. Vortex Medical was the subject of an acquisition agreement with AngioDynamics (transaction reported in news coverage).
#Endovascular devices / thrombus removal
Listed on CHV's portfolio; specific product or financing details are presented on the company portfolio page.
#Medical devices
CHV-listed portfolio company; Maxwell Health was acquired by Sun Life Financial (reported in CHV news item).
#Digital health / benefits administration software